Dubai, UAE – In a move described as a “historic moment in human medicine”, Professor and Professor of the Department of Genetics at the Blavatnik Institute, David Sinclair, announced that next month will witness the start of the first clinical trial on humans to test the possibility of reversing the aging process or slowing aging and treating associated diseases.
“We need to tackle all diseases at once, and that means ageing,” Sinclair said at the World Government Summit. “Aging is the cause of these diseases.”
He stressed that this technology could extend to giving people longer, healthier and more productive lives.
This redefines aging and transforms it from a stage of deterioration into a period in which vitality and activity can be maintained until the age of eighty and ninety.
He pointed out that using the three Yamanaka genes allows youth to return to cells by up to 75% within 6 weeks, without risking the creation of cancer cells.
Previous animal experiments have shown the ability to regrow tissue and repair optic nerves.
This led to the recovery of blindness in mice, as well as the treatment of brain, liver and kidney diseases.
The Yamanaka genes are four transcription factors (Oct4, Sox2, Klf4, c-Myc) discovered by Shinya Yamanaka in 2006.
They are used to reprogram differentiated adult cells to an embryonic stem cell-like state (induced abundant stem cells iPSCs).
This discovery enables tissue regeneration, reverses aging, and treats diseases.
